A collaborative research effort between the University of Michigan College of Pharmacy and the University of Texas MD Anderson Cancer Center has led to the development of a new nanoparticle therapy.
This innovative approach aims to improve the safety and effectiveness of cancer immunotherapy, which is a critical area of ongoing research in oncology.
The therapy utilizes manganese-based nanoparticles, which may offer a new avenue for enhancing treatment outcomes for cancer patients.